Title : CLK 2 is an oncogenic kinase and splicing regulator in breast cancer

Authors’ Affiliations: Department of Medical Oncology, and Center for Functional Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Department of Medicine and Pathology, Harvard Medical School, Boston, Massachusetts, USA. Department of Medicine and Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA. Seoul National University College of Medicine, Seoul, Korea. Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Department of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai, China. MD Anderson Cancer Center, Houston, TX. Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. Broad Institute, Cambridge, Massachusetts, USA. Present address: Eisai Co., Ltd., Tokyo, Japan. Present address: Boston Scientific, St. Paul, MN 55112, USA Present address: Maimonides Medical Center, Brooklyn, NY 11219, USA Present address: Daiichi Sankyo Co., Ltd., Tokyo, Japan